Announcement by Zhejiang East Asia Pharmaceutical Co., Ltd. on Receiving Drug Registration Certificate for Saxagliptin and Metformin Extended-Release Tablets

Securities Code: 605177
Securities Abbreviation: East Asia Pharmaceutical
Announcement No.: 2026-010

Bond Code: 111015
Bond Abbreviation: East Asia Convertible Bond

Zhejiang East Asia Pharmaceutical Co., Ltd. Announcement on the Approval of the Drug Registration Certificate for Sitagliptin Metformin Extended-Release Tablets

The company’s board of directors and all directors guarantee that this announcement contains no false records, misleading statements, or major omissions, and assume legal responsibility for the authenticity, accuracy, and completeness of its content.

Recently, Zhejiang East Asia Pharmaceutical Co., Ltd. (hereinafter referred to as “the Company”) received the “Drug Registration Certificate” issued by the National Medical Products Administration (hereinafter “NMPA”) for Sitagliptin Metformin Extended-Release Tablets (I) and (III). The relevant details are hereby announced as follows:

1. Basic Information of the Drug Registration Certificate

■

2. Information about the Drug

Sitagliptin Metformin Extended-Release Tablets, used in conjunction with diet and exercise, are suitable for adult patients with type 2 diabetes who are receiving sitagliptin and metformin treatment to improve blood sugar control. According to data from the NMPA website, as of the date of this announcement, companies in China that have obtained the registration certificate for this drug include Beijing Fuyuan Pharmaceutical Co., Ltd. and Shandong Qidu Pharmaceutical Co., Ltd. Data shows that the total sales of Sitagliptin Metformin Extended-Release Tablets in hospitals and pharmacies nationwide in the first three quarters of 2025 were approximately 404 million yuan.

3. Impact on the Company and Risk Reminder

The company’s acquisition of the “Drug Registration Certificate” for Sitagliptin Metformin Extended-Release Tablets (I) and (III) will help expand its formulation categories, enhance the market competitiveness of its products, and enrich the company’s experience in applying for formulation registration certificates, providing strong momentum for the long-term development of its formulation business.

The company attaches great importance to drug R&D, strictly controls quality and safety throughout the entire drug production process. However, due to the characteristics of the pharmaceutical industry, drug production and sales are susceptible to influences from national policies and market environment changes, which involve significant uncertainties. Investors are advised to make cautious decisions and be aware of investment risks.

This announcement is hereby issued.

Zhejiang East Asia Pharmaceutical Co., Ltd.
Board of Directors
March 16, 2026